| Title | A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin. | | Author(s) | Simoens S, Decramer M | | Institution | Katholieke Universiteit Leuven, Research Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Onderwijs en Navorsing 2, Herestraat 49, PO Box 521, 3000 Leuven, Belgium. steven.simoens@pharm.kuleuven.be | | Source | Expert Opin Pharmacother 2008 Jul; 9(10):1735-44. | | Abstract | BACKGROUND: Moxifloxacin, a fluoroquinolone, has demonstrated its safety and effectiveness in the management of community-acquired pneumonia, acute exacerbations of chronic bronchitis and acute bacterial sinusitis.
OBJECTIVE: The aim of this article was to provide a synthesis and critical appraisal of economic evaluations of the management of respiratory tract infections with moxifloxacin.
METHODS: Studies were included if they assessed the costs and consequences of moxifloxacin as compared with an alternative antimicrobial in the management of community-acquired pneumonia, acute exacerbations of chronic bronchitis or acute bacterial sinusitis.
RESULTS/
CONCLUSIONS: Treatment of community-acquired pneumonia, acute exacerbations of chronic bronchitis or acute bacterial sinusitis with moxifloxacin is equally or more effective and less expensive than treatment with other antimicrobials. | | Language | eng | | Pub Type(s) | Journal Article
Research Support, Non-U.S. Gov't
| | PubMed ID | 18570606 |
|
